loteprednol-etabonate and Corneal-Diseases

We report two patients who developed toxic keratopathy following high-dose cytarabine chemotherapy and whose symptoms resolved following topical loteprednol etabonate 0.5% treatment. A 25-year-old woman and a 26-year-old man with acute myeloid leukemia were referred to our department with symptoms of ocular discomfort, photophobia, and blurred vision after consolidation chemotherapy. Central corneal epithelial microcysts were observed bilaterally in both patients, and in vivo confocal microscopy showed highly reflective disseminated granular and irregular intraepithelial opacities, mainly in the basal epithelial layers. Loteprednol etabonate 0.5% relieved both patients' symptoms in less than a week, and the microcysts disappeared in 2 to 3 weeks of treatment. Although there is no standardized treatment protocol for cytarabine-induced corneal toxicity, dexamethasone 0.1% and prednisolone phosphate 1.0% were reported to be effective in the resolution of discomfort and symptoms. In the two patients we report herein, loteprednol etabonate 0.5% four times daily was also effective in suppressing the symptoms.

Topics: Adult; Anti-Allergic Agents; Antimetabolites, Antineoplastic; Cornea; Corneal Diseases; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Loteprednol Etabonate; Male; Microscopy, Confocal; Ophthalmic Solutions

To compare the efficiency and ocular side-effect profile of topical loteprednol applied to one eye and topical dexamethasone applied to the other eye in the early period on the same patient who has subepithelial infiltrates (SEI).. The patients who developed bilateral SEI following epidemic keratoconjunctivitis (EKC) were applied topical loteprednol on one eye (group 2) and topical dexamethasone on the other (group 1).. Decrease in the symptoms was faster in the dexamethasone group, but this difference between the groups was not statistically significant (p = 0.073). Both groups were found to have substantial recurrence. However, the difference between the groups was not statistically significant (p = 0.131).. The study has found that in the treatment of SEI, which developed after EKC, statistically similar results can be obtained with loteprednol, which is known to have fewer adverse effects.

Topics: Adenovirus Infections, Human; Administration, Ophthalmic; Adolescent; Adult; Anti-Allergic Agents; Child; Conjunctivitis, Viral; Corneal Diseases; Corneal Stroma; Dexamethasone; Epithelium, Corneal; Eye Infections, Viral; Female; Glucocorticoids; Humans; Loteprednol Etabonate; Male; Middle Aged; Ophthalmic Solutions; Prospective Studies; Treatment Outcome; Visual Acuity; Young Adult

To report a case of dendritic keratopathy secondary to ocular rosacea in a 62-year-old man.. Case report.. We discuss the ophthalmologic findings, management, and course in a patient with an unusual dendritic corneal lesion resistant to medical therapy. Other causes of dendritic lesions on the cornea were ruled out after investigation. The patient experienced symptomatic and objective improvement in the lesion with treatment of ocular rosacea.. This case represents an interesting presentation of rosacea with dendritic keratopathy associated with typical skin lesions.

Topics: Androstadienes; Bacitracin; Corneal Diseases; Doxycycline; Drug Therapy, Combination; Humans; Loteprednol Etabonate; Male; Middle Aged; Rosacea

Topics: Androstadienes; Anti-Inflammatory Agents; Biomarkers; Corneal Diseases; Drug Therapy, Combination; Fluorometholone; Humans; Infant; Loteprednol Etabonate; Male; Xanthogranuloma, Juvenile